Lynparza approved in China as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer
AstraZeneca and MSD’s Lynparza reduced the risk of disease progression or death by 70% in BRCAm advanced ovarian cancer after response to 1st-line platinum-based chemotherapy Only PARP inhibitor approved in this setting in ChinaAstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have received marketing authorisation from China’s National Medical Products Administration (NMPA) for Lynparza (olaparib) as a 1st-line maintenance treatment of adult patients with newly diagnosed advanced germline or